Aller au contenu principal
Accès ouvert déclaré 2025 article

Successful rapid desensitization to zoledronic acid in a multiple myeloma patient

1Citations signalées, ce qui n’est pas une note de qualité
1Institutions déclarées
1Pays d’affiliation déclarés

Rattachement africain : it. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

BACKGROUND: Multiple myeloma (MM) is a malignancy characterized by the proliferation of abnormal plasma cells in the bone marrow, leading to osteolytic lesions. This condition is accompanied by a serum accumulation of monoclonal immunoglobulin. Zoledronic acid (ZA) is a new-generation bisphosphonate commonly used to prevent bone complications. However, allergic reactions can pose challenges, potentially leading to ZA discontinuation. Thus, rapid desensitization (RD) has been proposed as a solution to continue treatment in patients with severe HR. RD consists in the induction of a temporary state of tolerance by administering increasing doses of the offending medication. METHODS: We present the case of a 57-year-old woman with MM who developed face angioedema, flushing with itching, dizziness and fever to ZA. Thus, an allergy work-up with skin prick test and intradermal test (IDT) with ZA were performed. Subsequently, considering the necessity of maintaining ZA treatment, a 3-dilution, 12-step RD infusion protocol was implemented. Skin tests were also repeated after three RD infusions. RESULTS: Skin tests showed positive IDT reactions to ZA confirming the hypersensitivity state of the patient to the medication. Then, the patient underwent RD procedures without any HR. Skin tests performed after three RD procedures were deemed negative. CONCLUSIONS: Here, we demonstrate successful management with RD in an MM patient with HR to ZA, providing a valuable therapeutic option for patients experiencing such reactions. The effectiveness of RD to ZA was confirmed by the negative response to skin tests after 3 RD procedures. Nevertheless, further research is needed to refine RD protocols and establish their safety and efficacy for patients with HR to ZA. Standardized in vitro testing may also improve the diagnosis and management of ZA hypersensitivity.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Successful rapid desensitization to zoledronic acid in a multiple myeloma patient
Date Crossref
26/03/2025
Éditeur
Springer Science and Business Media LLC
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Où se fait cette recherche

  • University of Bari Aldo Moro pays non établi dans la notice
    Université ou école supérieure
  • School of Medicine Department of Precision and Regenerative Medicine and Ionian Area-(DiMePRe-J) pays non établi dans la notice
    Université ou école supérieure
  • University of Bari "Aldo Moro" Medical School Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J) pays non établi dans la notice
    Université ou école supérieure

University of Bari Aldo Moro, Department of Precision and Regenerative Medicine and Ionian Area-(DiMePRe-J) — School of Medicine et Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J) — University of Bari "Aldo Moro" Medical School.

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Bone health and treatmentsMultiple Myeloma Research and TreatmentsDrug-Induced Adverse Reactions

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.